|Study Description:||The goal of the Phase I portion of this clinical research study is to check the |
safety of a drug called Rigosertib (ON 01910.Na) when given to patients with
AML, ALL, or an MPN.
The goal of the Phase II portion of this study is to learn if rigosertib can
help to control the disease in patients with AML, ALL, or an MPN. The safety
of this drug will continue to be studied.